Bermekimab

Bermekimab ; ;
Trade names	Xilonix
Synonyms	MABp1 ; ; ;
Routes	intravenous ; ; ; ; ; ;
Identifiers
CAS Number	1401965-15-8 ; ;
ChemSpider	none
UNII	N6SVN735GY
KEGG	D11253 ;
Chemical data ;
Chemical formula	C6464H10024N1736O2000S44
Molecular weight	145.5 g/mol ; ; ;

Bermekimab^[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).^[2] As of 2017^[update][[Category:Articles containing potentially dated statements from Expression error: Unexpected < operator.]], bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer^[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.^[4]

Bermekimab is being developed by XBiotech Inc.^[5]

References[edit]

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
↑ "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study".The Lancet Oncology.May 2014;15(6)
656-66.doi:10.1016/S1470-2045(14)70155-X.Full text.
↑ A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)(link). ClinicalTrials.gov.U.S. National Institutes of Health.
↑ A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis(link). ClinicalTrials.gov.U.S. National Institutes of Health.
↑ Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology(link). www.xbiotech.com.XBiotech.

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.

[2] "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study".The Lancet Oncology.May 2014;15(6)
656-66.doi:10.1016/S1470-2045(14)70155-X.Full text.

[3] A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)(link). ClinicalTrials.gov.U.S. National Institutes of Health.

[4] A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis(link). ClinicalTrials.gov.U.S. National Institutes of Health.

[5] Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology(link). www.xbiotech.com.XBiotech.

[1]

[2]

[3]

[4]

[5]